Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 6 studies | 26% ± 6% | |
hematopoietic precursor cell | 4 studies | 23% ± 11% | |
classical monocyte | 4 studies | 23% ± 6% | |
epithelial cell | 4 studies | 37% ± 13% | |
endothelial cell | 4 studies | 20% ± 4% | |
regulatory T cell | 4 studies | 16% ± 0% | |
non-classical monocyte | 3 studies | 28% ± 6% | |
dendritic cell | 3 studies | 33% ± 8% | |
plasmacytoid dendritic cell | 3 studies | 22% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 3 studies | 20% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2938.66 | 1445 / 1445 | 100% | 31.53 | 183 / 183 |
kidney | 100% | 4295.71 | 89 / 89 | 100% | 59.44 | 901 / 901 |
lung | 100% | 3165.98 | 578 / 578 | 100% | 51.05 | 1155 / 1155 |
prostate | 100% | 3367.57 | 245 / 245 | 100% | 56.60 | 502 / 502 |
stomach | 100% | 2833.32 | 359 / 359 | 100% | 35.90 | 286 / 286 |
thymus | 100% | 4854.05 | 653 / 653 | 100% | 93.12 | 605 / 605 |
uterus | 100% | 3279.51 | 170 / 170 | 100% | 50.81 | 459 / 459 |
brain | 100% | 2770.82 | 2638 / 2642 | 100% | 60.79 | 705 / 705 |
breast | 100% | 3512.94 | 459 / 459 | 100% | 66.90 | 1116 / 1118 |
ovary | 100% | 3770.15 | 180 / 180 | 100% | 40.26 | 429 / 430 |
pancreas | 100% | 1886.73 | 327 / 328 | 100% | 49.03 | 178 / 178 |
skin | 100% | 2945.30 | 1808 / 1809 | 100% | 46.32 | 470 / 472 |
liver | 100% | 2042.93 | 226 / 226 | 100% | 38.19 | 404 / 406 |
bladder | 100% | 3162.24 | 21 / 21 | 99% | 49.89 | 501 / 504 |
intestine | 100% | 3302.46 | 966 / 966 | 99% | 44.71 | 523 / 527 |
adrenal gland | 100% | 6399.88 | 258 / 258 | 99% | 57.94 | 228 / 230 |
adipose | 100% | 3393.50 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3747.20 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 60.06 | 29 / 29 |
spleen | 100% | 4337.21 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 44.60 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 15.78 | 1 / 1 |
heart | 99% | 1779.91 | 855 / 861 | 0% | 0 | 0 / 0 |
muscle | 99% | 1666.73 | 797 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 60.18 | 79 / 80 |
peripheral blood | 99% | 4241.82 | 916 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0046037 | Biological process | GMP metabolic process |
GO_0006144 | Biological process | purine nucleobase metabolic process |
GO_1902560 | Cellular component | GMP reductase complex |
GO_0005829 | Cellular component | cytosol |
GO_0003920 | Molecular function | GMP reductase activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | GMPR2 |
Protein name | GMP reductase (EC 1.7.1.7) GMP reductase (GMPR) (EC 1.7.1.7) (Guanosine 5'-monophosphate oxidoreductase) (Guanosine monophosphate reductase) Guanosine monophosphate reductase 2 GMP reductase 2 (GMPR 2) (EC 1.7.1.7) (Guanosine 5'-monophosphate oxidoreductase 2) (Guanosine monophosphate reductase 2) |
Synonyms | GMPR hCG_40198 |
Description | FUNCTION: Catalyzes the irreversible NADPH-dependent deamination of GMP to IMP. It functions in the conversion of nucleobase, nucleoside and nucleotide derivatives of G to A nucleotides, and in maintaining the intracellular balance of A and G nucleotides . Plays a role in modulating cellular differentiation . . FUNCTION: Catalyzes the irreversible NADPH-dependent deamination of GMP to IMP. It functions in the conversion of nucleobase, nucleoside and nucleotide derivatives of G to A nucleotides, and in maintaining the intracellular balance of A and G nucleotides. . FUNCTION: Catalyzes the irreversible NADPH-dependent deamination of GMP to IMP. It functions in the conversion of nucleobase, nucleoside and nucleotide derivatives of G to A nucleotides, and in maintaining the intracellular balance of A and G nucleotides. . FUNCTION: Catalyzes the irreversible NADPH-dependent deamination of GMP to IMP. It functions in the conversion of nucleobase, nucleoside and nucleotide derivatives of G to A nucleotides, and in maintaining the intracellular balance of A and G nucleotides. . FUNCTION: Catalyzes the irreversible NADPH-dependent deamination of GMP to IMP. It functions in the conversion of nucleobase, nucleoside and nucleotide derivatives of G to A nucleotides, and in maintaining the intracellular balance of A and G nucleotides. . |
Accessions | H0YNS9 ENST00000647320.3 [Q9P2T1-1] H0YMG3 H0YNJ6 H0YL68 ENST00000559287.5 ENST00000642276.1 [Q9P2T1-1] ENST00000559409.5 A0A0B4J281 H0YKK3 ENST00000557854.5 ENST00000399440.7 [Q9P2T1-1] ENST00000558483.5 ENST00000559836.5 [Q9P2T1-1] ENST00000420554.6 [Q9P2T1-2] H0YMW6 H0YK13 H0YN22 ENST00000558748.1 Q6PKC0 H0YN74 ENST00000558788.1 ENST00000645781.1 [Q9P2T1-2] H0YKE1 ENST00000558932.1 H0YLB8 H0YMR9 ENST00000560139.5 ENST00000644066.1 [Q9P2T1-1] H0YLV5 H0YK71 ENST00000559102.1 H0YMV5 ENST00000561035.5 ENST00000355299.8 [Q9P2T1-1] ENST00000561130.5 ENST00000643803.1 [Q9P2T1-3] ENST00000456667.7 [Q9P2T1-3] H0YNH0 ENST00000561038.5 ENST00000559104.5 ENST00000558279.5 Q86SZ5 Q9P2T1 ENST00000558865.5 ENST00000559910.5 H0YMB3 ENST00000559943.1 ENST00000558760.5 ENST00000559479.1 |